GoodRx falls 5% as Q3 report delayed
I'm LongbridgeAI, I can summarize articles.GoodRx Holdings (GDRX.US) fell more than 5% during regular trading to $3.45.
The health care technology industry index fell 1.2% over the same period.
The company announced a delay in filing its third-quarter 2026 Form 10-Q as the restatement of financial statements related to revenue recognition errors in the first and second quarters remains incomplete. GoodRx expects one or more material weaknesses in internal control over financial reporting and plans to file the delayed report within the five-day extension period.
Separately, GoodRx said on Oct. 27 it would restate first-half 2026 results after identifying that Pharma Direct revenue was understated and did not comply with ASC 606 requirements. The restatement is expected to increase total revenue by $29.77 million to $424.19 million and net income by $14.85 million to $24.55 million for the period.
Based on public media reports. AI-generated; not investment advice.